Summary
This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the
safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect
on biomarkers of XL092 administered alone, in combination with atezolizumab, and in
combination with avelumab to subjects with advanced solid tumors.